BREAKTHROUGHS WITHIN MONOCLONAL ANTIBODIES MARKET


HIV stands for Human Immunodeficiency Virus. The Virus attacks and destroys the cells that make up a person’s immune system, leaving their body unable to defend itself and more susceptible to contracting diseases. HIV is transmitted through sexual contact and can last for years or be lifelong. The virus infects 37 million people and kills about 1.2 million people every year. There is no cure for HIV but BioClonetics seems to have found a way to target and destroy the virus using monoclonal antibodies, a breakthrough in antibodies market

Download free sample report : http://www.marketdataforecast.com/market-reports/global-antibodies-market-1177/request-sample

ABOUT MONOCLONAL ANTIBODIES

Monoclonal Antibodies (mAbs) are molecules produced in a laboratory that act as valuable reinforcements and a second line of defense against diseases that your immune system can’t fight off on it’s own. They are classified as Murine, Chimeric, Humanized, and Human monoclonal antibodies each used for different indications. Given pretty much any substance, a monoclonal antibody can be produced that specifically binds to that substance which can be used for detection or purification of that substance.

THE HIV BREAKTHROUGH

BioClonetics Immunotherapeutics, a biotechnology company has, using their proprietary methodology have produced fully human IgG1 monoclonal antibodies which can be used to treat infectious diseases. The company creates human cell lines that produce human antibodies which are used to fight infectious diseases. They have created proprietary cell lines that produce antibodies that target and neutralize infectious diseases including Influenza, Tetanus, Diphtheria, and HIV.

Inquire before buyinghttp://www.marketdataforecast.com/market-reports/global-antibodies-market-1177/inquire

They are in the final development stage of the antibody that targets HIV which has been found to be 100% effective against over 92% of the HIV strains. The antibody can be developed to as a therapeutic vaccine to prevent uninfected people from contracting the virus.

ADVANTAGES TO STANDARD ART (Antiretroviral Therapy) TREATMENT

The current standard treatment for HIV infection is to administer the infected person with an anti-HIV cocktail. This is combination of multiple antiretroviral medicines. Antiretroviral medicine slows the rate at which the HIV virus multiplies in the body, thus inhibiting the disease. The treatment with monoclonal antibodies will be far superior as it:

  • Is more effective and non-toxic
  • Will not require lifetime treatment
  • Is far less expensive than the ART

This goes to show how useful monoclonal antibodies can be and the potential they have in treating deadly diseases. The major pharmaceutical companies that believe in the potential of mAbs include Abbvie Inc., A.G Scientific, Pfizer Inc., Abbott Diagnostics, and Roche.

Currently more than 40% of the revenue of biopharmaceuticals are of monoclonal antibodies with recombinant proteins in second place with 20%. The antibodies market is growing at a CAGR of 11.20%, currently at USD 95.22 Billion which is projected to reach USD 161.90 Billion by 2021. Of the current market share more than USD 80 Billion is of monoclonal antibodies.

The market is growing at this rapid rate because of the continuous development of innovative products. Also these low cost solutions to a variety of medical conditions is welcomed with open arms in cost sensitive markets. The rising levels in chronic illnesses which can be treated with mAbs like Rheumatoid Arthrits, Psoriasis, HIV, cancer, Crohn’s disease, and leukemia also increase the demand for the cheap and innovative treatments. Due to the huge potential, the regulatory authorities like the FDA streamline the approval process for the drugs making it easier to start the trials and introduce it to the market like in the case of the US FDA approving the addition of moderate to severe Fingernail psoriasis data to its HUMIRA making it the only biological treatment with data on fingernail psoriasis in the US.

Once some of the issues with side effects with antibodies treatment and the cost of production of the antibodies are sorted out the market should soar to new heights.

Visit here for more reports: http://www.marketdataforecast.com


Share this post:

Recent Posts

7 Comments

  1. Jack says:

    Ԝould Becoming A Freelance Paralegal Be A Gоod Chօice For You?

  2. W/ Catwoman, Police, Pink Spidergirl, Ariel mermaid h.

  3. We assess a 20% restocking fee on all returns.

  4. Thanks for posting this.

  5. Be realistic about the cost of dog food.

Leave a Comment

51 − 50 =